| Similar Articles |
|---|
 |
The Motley Fool
September 5, 2006
Rich Smith |
Foolish Forecast: ThermoGenesis Begins The medical equipment maker is due to report fiscal fourth-quarter and full-year 2006 numbers. Will they chill or warm investors hearts?   |
The Motley Fool
November 30, 2004
Rich Smith |
Breaking Rules and Saving Lives Cord blood offers an ethical means of using stem cells to heal illness. While two top companies in the field are private, over the counter traded Cryo-Cell lost as much money as it collected in revenues last year. |
The Motley Fool
September 11, 2006
Rich Smith |
ThermoGenesis' Cold, Hard Cash Sales may be light, but the medical equipment maker's wallet is heavy. Investors, take note. |
BusinessWeek
June 27, 2005
Arlene Weintraub |
Stem Cells To Go ViaCell's goal is to mass-produce stem cells from umbilical cord blood. |
The Motley Fool
May 16, 2007
Mike Havrilla |
Biotech Prospects for a Sizzling Summer Consider these biotech stocks to make your portfolio sizzle this summer. Advanced Life Sciences... Depomed... Theravance... etc. |
BusinessWeek
December 6, 2004
Catherine Arnst |
Cord Blood To The Rescue A study in the Nov. 25 issue of The New England Journal of Medicine confirms that stem cells in blood extracted from the umbilical cords of newborns can help leukemia patients |
Salon.com
July 17, 2000
Alix Christie |
The cord-blood controversy First we were supposed to eat the placenta. Now we're supposed to freeze it. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
The Motley Fool
April 14, 2008
Brian Orelli |
Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost. |
Pharmaceutical Executive
October 1, 2012
Ben Comer |
Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures. |
The Motley Fool
May 2, 2007
Mike Havrilla |
Heads Up, Biotech Investors: Chapter 2 Get to know the timing of major catalysts for stocks that may be on your biotech watch list. |
The Motley Fool
February 2, 2005
Rich Duprey |
Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note. |
BusinessWeek
May 24, 2004
Arlene Weintraub |
Want To Bank Your Own Stem Cells? One Los Angeles startup believes everyone should, to be ready when regenerative therapies start hitting the market |
The Motley Fool
December 22, 2003
Alyce Lomax |
Losing Faith in Inspire Delay for its dry-eye treatment leaves investors uninspired. |
The Motley Fool
August 31, 2007
Brian Orelli |
A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending. |
Reason
July 2004
Caroline Waters |
Bloody Shame Unnecessary regulations are making American blood banks run dry. |
Pharmaceutical Executive
January 1, 2006
Kenneth I. Kaitin |
Opinion: Memo to von Eschenbach FDA's acting commissioner has an opportunity to clarify a lot of misconceptions about the agency's role in regulating drug safety. His first order of business should be to explain exactly what FDA doesn't do. |
Popular Mechanics
December 16, 2008
Michael Milstein |
Bringing Stem Cells to War: Meet the Blood Pharmers Fresher blood is better than stale: It carries more oxygen and, when transfused into patients, speeds recovery. |
The Motley Fool
November 9, 2004
Charly Travers |
Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works. |
Pharmaceutical Executive
February 1, 2006
Bryan Luce |
Back Page: Taking Hold of the Wheel Healthcare decision makers do not consistently consider drugs' value. FDA needs to be pressured to change its stance on communicating economic evidence. |
The Motley Fool
August 17, 2007
Brian Orelli |
Fewer Drug Approvals? Buy! Stricter standards at the FDA could create a buying opportunity. Drug approvals are down one third this year, creating a lot of value in pharmaceutical and biotech companies. Just choose your medicines carefully. |
The Motley Fool
April 8, 2008
Brian Lawler |
FDA Approvals ... Increase? So far in 2008, the agency has given more drugs a thumbs-up than this time in 2007. Take a look at which companies received approvals. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Bio-IT World
Dec 2005/Jan 2006
Maureen McDonough |
The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line. |
Pharmaceutical Executive
August 1, 2012
Jill Wechsler |
Fleshing Out FDASIA Medical apps, e-submissions, counterfeit drugs, and imports tucked into fairly "clean" user-fee renewal legislation. In late June leading legislators reached across party lines to quickly approve the Food and Drug Administration Safety and Innovation Act. |
IndustryWeek
October 19, 2011 |
FDA: A Future Innovation Partner? Could the Food and Drug Administration reform itself to help manufacturers create new medical technologies? |
CIO
March 15, 2006
Allan Holmes |
Rx for Risk As it revamps its workflow processes, the FDA is relying on technology to reduce the risk that unsafe substances will get into the market. |
The Motley Fool
October 10, 2005
Stephen D. Simpson |
The FDA: Boon, Bane, Whipping Boy Everyone wants the FDA to be faster, better, and cheaper, but that may not be a credible expectation. Investors would do well to keep an eye on the FDA because its policies and pressures ultimately filter down to our medicine cabinets, wallets, and portfolios. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
Pharmaceutical Executive
December 1, 2013 |
FDA Pursues Delicate Balancing Act The Agency struggles to ensure access to needed medicines while minimizing potential risks, writes Jill Wechsler. |
Pharmaceutical Executive
March 1, 2012
Ron Cohen |
FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership. |
